topotecan kabi
fresenius kabi oncology plc - topotekanas - koncentratas infuziniam tirpalui - 1 mg/ml - topotecan
zondaron
sopharma ad - ondansetronas - injekcinis ar infuzinis tirpalas - 2 mg/ml - ondansetron
aprepitant sandoz
sandoz d.d. - aprepitantas+aprepitantas - kietosios kapsulės - 125 mg + 80 mg - aprepitant
opinasin
us pharmacia sp. z o.o. - paracetamolis/pseudoefedrino hidrochloridas/dekstrometorfano hidrobromidas/chlorfenamino maleatas - plėvele dengtos tabletės - 500 mg/30 mg/15 mg/2 mg - paracetamol, combinations excl. psycholeptics
ondansetron aurobindo
actiofarma, uab - ondansetronas - plėvele dengtos tabletės - 8 mg - ondansetron
grinite thermal [cedinex]
us pharmacia sp. z o.o. - paracetamolis/pseudoefedrino hidrochloridas/dekstrometorfano hidrobromidas/chlorfenamino maleatas - milteliai geriamajam tirpalui - 650 mg/60 mg/20 mg/4 mg - paracetamol, combinations excl. psycholeptics
ondansetron actiofarma
actiofarma, uab - ondansetronas - plėvele dengtos tabletės - 8 mg - ondansetron
gripex
us pharmacia sp. z o.o. - paracetamolis/pseudoefedrino hidrochloridas/dekstrometorfano hidrobromidas - plėvele dengtos tabletės - 500 mg/30 mg/15 mg - paracetamol, combinations excl. psycholeptics
ondansetron kalceks
as kalceks - ondansetronas - injekcinis ar infuzinis tirpalas - 2 mg/ml - ondansetron
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antinavikiniai vaistai - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.